CareDx Advances Patient Care with AlloSure 3.0
- Better care with a new minimum of only one tube of blood required
- Better science with the lowest limit of detection now at 0.12%
- Better insights by appropriately stratifying patients with T-cell mediated rejection (TCMR)
“From our analysis of AlloSure in these patients, we found the measure of organ injury can discriminate those who are at risk and those who are not, allowing the future consideration of potential immunotherapy optimization based on AlloSure changes,” said
“A patient recently shared with me his experience with the regular lab workups is painful, with so many tubes of blood removed. We strive to create solutions that can meet all transplant patient needs, down to the youngest recipient who may not have much blood to give,” said
For more information, please visit: www.CareDx.com.
Chief Marketing Officer,
Chief Financial Officer,
Source: CareDx, Inc.